â– LECTURE OVERVIEW: McArdle Disease (Glycogen Storage Disease Type V) is a benign, muscle-specific metabolic disorder characterized by an inability to mobilize skeletal muscle energy stores during exercise.
â– MYOCELLULAR PATHWAYS:
1. Specific Myophosphorylase Mutation: Caused by autosomal recessive mutations in the PYGM gene, which encodes the skeletal muscle-specific isoform of Glycogen Phosphorylase (myophosphorylase).
2. Isolation of Defect: The hepatic isoform (PYGL) and cardiac isoform are intact; thus, blood glucose regulation and cardiac performance are completely unimpaired.
3. Muscle Glycogen Splitting Deficit: Skeletal muscle cells cannot break glycogen into glucose-1-phosphate, leaving working muscles depleted of immediate anaerobic fuel during the onset of physical exertion.
4. Kinetic Blockade: Lactic acid production is severely impaired, as the glycolytic substrates are unavailable to undergo fermentation.
â– TOXICOLOGICAL OVERDOSAGE PROTOCOL:
Toxic absorption or cumulative exposure results in receptor saturation, chemical cell damage, or severe secondary target-organ failure. Immediate toxicological profiles dictate serum or urine screens.
â– ACUTE TOXICOLOGICAL PROFILE:
High cumulative chemical exposure or accidental overdose triggers systemic receptor overload, cellular injury, and metabolic acidosis.
[HY-BOARD-1179]
🌟 Dynamic Clinical Key:
Classic presentation includes severe muscle cramping, fatigue, and pain during the first few minutes of strenuous exercise, which improves upon resting for a few minutes (the 'second wind' phenomenon, driven by fatty acid mobilization and increased femoral blood flow). Forearm ischemic exercise reveals flat venous lactate curve but a normal rise in ammonia. Administer physiological antidotes and active elimination therapies (activated charcoal or hemodialysis) without delay. Immediate administration of physiological charcoal or specific receptor antagonists is lifesaving.